What is the equity of Immunitybio this year?
Immunitybio has equity of -586.99 M USD this year.
Immunitybio Equity 2024
Immunitybio Equity
-586.99 M USD
Immunitybio Dividend yield
Ticker
IBRX
ISIN
US45256X1037
WKN
A2QQ2E
In 2024, Immunitybio's equity was -586.99 M USD, a 31.23% increase from the -447.3 M USD equity in the previous year.
Immunitybio Aktienanalyse
What does Immunitybio do?
Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Immunitybio's Equity
Immunitybio's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Immunitybio's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Immunitybio's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Immunitybio's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Immunitybio’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Immunitybio Stock
What was the equity of Immunitybio compared to the previous year?
The equity of Immunitybio has increased/decreased by 31.23% increased compared to the previous year.
What impact does a high equity have on investors of Immunitybio?
A high equity is advantageous for investors of Immunitybio as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Immunitybio?
A low equity can be a risk for investors of Immunitybio, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Immunitybio affect the company?
An increase in equity of Immunitybio can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Immunitybio affect the company?
A reduction in equity of Immunitybio can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Immunitybio?
Some factors that can affect the equity of Immunitybio include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Immunitybio so important for investors?
The equity of Immunitybio is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Immunitybio take to change the equity?
To change equity, Immunitybio can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Immunitybio pay?
Over the past 12 months, Immunitybio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunitybio is expected to pay a dividend of 0 USD.
What is the dividend yield of Immunitybio?
The current dividend yield of Immunitybio is .
When does Immunitybio pay dividends?
Immunitybio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immunitybio?
Immunitybio paid dividends every year for the past 0 years.
What is the dividend of Immunitybio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immunitybio located?
Immunitybio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immunitybio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immunitybio from 5/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/18/2024.
When did Immunitybio pay the last dividend?
The last dividend was paid out on 5/18/2024.
What was the dividend of Immunitybio in the year 2023?
In the year 2023, Immunitybio distributed 0 USD as dividends.
In which currency does Immunitybio pay out the dividend?
The dividends of Immunitybio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immunitybio
Our stock analysis for Immunitybio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunitybio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
